NONSURGICAL

Galderma launches two new dermal fillersGalderma receives FDA approval for Restylane Refyne and Defyne, two next-generation HA fillers.
Rapamycin may slow agingUsed as a transplant rejection inhibitor, therapy for renal cell carcinoma and as a stent coating, the rapamycin compound may also increase lifespan.
Cost-effective correction of mid-face volume lossResearchers examine the practical application of a significantly lower dose of HA for midface volume correction compared with that used in pivotal trials.
Toxin vs toxin: How do you choose?Botox, Dysport and Xeomin may share similarities, but several factors can affect the best way to choose which is best for your individual patients.
An authentic picture of the aging faceThink you know your way around the aging face? Think again. New research challenges assumptions about how the face changes over time.
Measuring nonsurgical fat reductionResearchers offer a reproducible solution to quantify nonsurgical fat reduction results.
ABCs and 123s of ona-, abo- and incobotulinumtoxinA
ABCs and 123s of ona-, abo- and incobotulinumtoxinAA recently published stepwise approach to treating wrinkles provides a template for achieving safe, effective results with FDA-approved neurotoxins.
No-touch lip enhancement
No-touch lip enhancementAvoiding needle injection directly into the mucosa decreases swelling and bruising both during and after the procedure.
Next-gen RF combo treatmentA study using a combination bipolar RF+IR and fractionated RF protocol shows significant improvement in skin quality and delivers high marks in patient satisfaction.
Laser treatment for permanent filler complicationsResearchers offer a novel approach and treatment algorithm for removing permanent fillers.

Poll

View Results